Diakovere Henriettenstift
- Address
- Marienstr. 72-90, 30171 Hanover, Germany
Diakovere Henriettenstift - Breast Cancer Research Center
Diakovere Henriettenstift is a specialized clinical research center focusing on advanced breast cancer treatment strategies. The center conducts pivotal trials investigating novel therapeutic approaches for patients at high risk of disease recurrence, with particular expertise in HER2-positive and HER2-negative breast cancer subtypes.
- Early HER2-positive breast cancer with high recurrence risk following preoperative therapy
- HER2-negative breast cancer in patients with high relapse risk after neoadjuvant treatment
- Evaluation of targeted antibody-drug conjugates including trastuzumab emtansine and sacituzumab govitecan
- Adjuvant immunotherapy strategies combining checkpoint inhibitors like atezolizumab with targeted agents
The center's research portfolio emphasizes invasive disease-free survival outcomes and contributes to establishing evidence-based treatment protocols for breast cancer patients requiring intensive therapeutic intervention after standard preoperative or neoadjuvant regimens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Phenonet Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diakovere Henriettenstift
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Therapy with Capecitabine in Stage II Colon and Rectal Cancer Patients with ctDNA Positivity Post-Resection | Technische Universitat Dresden | Phase III | Not Recruiting | Dec 2019 | Jan 2026 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 2 | Unknown | 2019-12-04 | 2020-10-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.